Our clinical and laboratory data suggest that levamisole should be added to the list of immunotherapeutic agents that have direct actions on podocytes and point to the usefulness of levamisole in the treatment of adult as well as paediatric patients.

Keywords:
levamisole, minimal change nephropathy, podocyte, primary nephrotic syndrome, steroid-sensitive nephrotic syndrome
© The Authors Journal compilation © 2015 Biochemical Society
2015
You do not currently have access to this content.